Floatz logo

Hydroxychloroquine

Ras (Kras or Nras) Gene Mutation

N.N. Petrov National Medical Research Center of OncologySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Ras (Kras or Nras) Gene Mutation cohort.

Asset / SponsorPhaseRating
Binimetinib
N.N. Petrov National Medical Research Center of Oncology
Phase 2CCC
Cobimetinib
N.N. Petrov National Medical Research Center of Oncology
Phase 2CCC
Leflunomide
N.N. Petrov National Medical Research Center of Oncology
Phase 2CCC
gsk1120212
N.N. Petrov National Medical Research Center of Oncology
Phase 2CCC
ik-595
Ikena Oncology
Phase 1CC

Same molecule, other indications

Hydroxychloroquine is also rated in:

cutaneous melanomaDormant
B
Indicative ·
61 / 100
View asset →
prostate cancerDormant
B
Indicative ·
60 / 100
View asset →
pancreatic adenocarcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →